Compare Stocks

→ The only accurate crypto trading system I know … (From Weiss Ratings) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTC Benitec Biopharma	$6.72 -2.0%	$4.99	$1.86 ▼ $9.01	$17.78M	1.03	213,075 shs	66,355 shs
NVUS Novus Therapeutics	$1.97 -8.8%	$13.23	$4.50 ▼ $27.32	$2.83M	2.07	78,851 shs	100,706 shs
VVUS VIVUS		$0.37	$0.44 ▼ $4.75	$7.33M	-0.84	1.44 million shs	2.03 million shs
XTLB XTL Biopharmaceuticals	$2.56 -1.2%	$3.99	$1.73 ▼ $6.69	$14.11M	1.21	136,363 shs	33,017 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTC Benitec Biopharma	-2.04%	+40.00%	+33.33%	+128.57%	+79.76%
NVUS Novus Therapeutics	-2.48%	+25.48%	-4.83%	+8.84%	-13.22%
VVUS VIVUS	0.00%	0.00%	0.00%	0.00%	0.00%
XTLB XTL Biopharmaceuticals	-1.16%	+3.64%	-8.90%	+212.20%	+109.82%

How to camouflage a factory of 53,000 workers (Ad)

"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."

Get the full story here.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BNTC Benitec Biopharma	1.5597 of 5 stars	3.5	3.0	0.0	0.0	2.3	0.8	0.0
NVUS Novus Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VVUS VIVUS	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
XTLB XTL Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNTC Benitec Biopharma	3.00	Buy	$16.00	138.10% Upside
NVUS Novus Therapeutics	N/A	N/A	N/A	N/A
VVUS VIVUS	N/A	N/A	N/A	N/A
XTLB XTL Biopharmaceuticals	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest NVUS, BNTC, XTLB, and VVUS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
4/22/2024	BNTC Benitec Biopharma	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$10.00 ➝ $16.00
2/15/2024	BNTC Benitec Biopharma	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$8.00 ➝ $10.00

(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNTC Benitec Biopharma	$80K	217.56	N/A	N/A	$0.12 per share	56.00
NVUS Novus Therapeutics	N/A	N/A	N/A	N/A	$13.13 per share	N/A
VVUS VIVUS	$69.76M	0.00	N/A	N/A	($6.50) per share	0.00
XTLB XTL Biopharmaceuticals	N/A	N/A	N/A	N/A	$0.73 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNTC Benitec Biopharma	-$19.56M	N/A	0.00	∞	N/A	N/A	-204.34%	-142.81%	5/20/2024 (Estimated)
NVUS Novus Therapeutics	-$16.01M	-$21.58	N/A	N/A	N/A	N/A	-133.49%	-30.52%	N/A
VVUS VIVUS	-$31.50M	-$2.96	N/A	N/A	N/A	-39.28%	N/A	-12.18%	N/A
XTLB XTL Biopharmaceuticals	-$1.35M	-$0.42	N/A	∞	N/A	N/A	-73.05%	-68.83%	5/21/2024 (Estimated)

Latest NVUS, BNTC, XTLB, and VVUS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
2/13/2024	Q2 2024	BNTC Benitec Biopharma	N/A	-$2.64	-$2.64	-$2.64	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNTC Benitec Biopharma	N/A	N/A	N/A	N/A	N/A
NVUS Novus Therapeutics	N/A	N/A	N/A	N/A	N/A
VVUS VIVUS	N/A	N/A	N/A	N/A	N/A
XTLB XTL Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNTC Benitec Biopharma	0.01	3.62	3.62
NVUS Novus Therapeutics	N/A	18.78	18.78
VVUS VIVUS	N/A	0.43	0.28
XTLB XTL Biopharmaceuticals	N/A	14.09	N/A

Ownership

Institutional Ownership

Company	Institutional Ownership
BNTC Benitec Biopharma	52.19%
NVUS Novus Therapeutics	N/A
VVUS VIVUS	7.32%
XTLB XTL Biopharmaceuticals	4.40%

Insider Ownership

Company	Insider Ownership
BNTC Benitec Biopharma	4.30%
NVUS Novus Therapeutics	2.20%
VVUS VIVUS	12.00%
XTLB XTL Biopharmaceuticals	29.00%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
BNTC Benitec Biopharma	18	2.59 million	2.48 million	No Data
NVUS Novus Therapeutics	7	1.44 million	N/A	Not Optionable
VVUS VIVUS	57	17.87 million	N/A	Optionable
XTLB XTL Biopharmaceuticals	N/A	5.45 million	3.87 million	Not Optionable

NVUS, BNTC, XTLB, and VVUS Headlines

Source	Headline
	U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.03% msn.com - March 20 at 8:50 PM
	US Stocks Edge Lower Ahead Of Fed's Decision; General Mills Earnings Top Views msn.com - March 20 at 3:48 PM
	Dow Surges 350 Points; Fed Holds Rates Steady markets.businessinsider.com - March 20 at 3:48 PM
	Crude Oil Surges 2%; Signet Jewelers Shares Spike Higher markets.businessinsider.com - March 20 at 3:48 PM
	XTL To Aquire The Social Proxy globenewswire.com - March 20 at 10:15 AM
	XTL Biopharmaceuticals Ltd ADR (XTLB) investing.com - February 17 at 10:28 AM
	Call for Proposals raps.org - February 11 at 2:00 PM
	XTL Biopharmaceuticals Ltd (H2K2.MU) finance.yahoo.com - October 23 at 11:13 PM
	XTL Biopharmaceuticals Ltd.: XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency finanznachrichten.de - October 23 at 12:16 AM
	XTL Biopharmaceuticals Ltd.: XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in Israel finanznachrichten.de - October 21 at 8:22 AM
	XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in Israel finance.yahoo.com - October 20 at 7:35 PM
	XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency finance.yahoo.com - October 20 at 7:35 PM
	Is X T L Biopharmaceuticals Ltd (ADR) (XTLB) Stock a Good Investment? aaii.com - March 30 at 3:19 PM
	XTLB XTL Biopharmaceuticals Ltd. seekingalpha.com - October 1 at 8:47 PM
	X T L Biopharmaceuticals Ltd reuters.com - August 8 at 10:32 PM
	LIFE, TBLT and XTLB among pre market gainers seekingalpha.com - July 23 at 7:53 AM
	XTL Biopharmaceuticals Year to Date Total Returns (Daily) ycharts.com - December 18 at 11:24 PM
	XTL Biopharmaceuticals Dividend Per Share (TTM) ycharts.com - December 18 at 1:03 AM
	XTL Biopharmaceuticals Ltd. (XTLB) uk.finance.yahoo.com - December 15 at 10:18 AM
	X.T.L. Biopharmaceuticals Ltd. - ADR money.usnews.com - September 26 at 12:03 AM
	XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) Up 1.8% This Year: What Should You Expect Next? stocksregister.com - August 23 at 4:44 PM
	Is XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) Expensive At $4.67? Here’s How To Know. marketingsentinel.com - August 20 at 5:09 PM
	How Is XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) Expected To Fare In The Coming Months? marketingsentinel.com - July 26 at 9:30 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Benitec Biopharma

NASDAQ:BNTC

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

Novus Therapeutics

NASDAQ:NVUS

Novus Therapeutics, Inc., a specialty pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California.

VIVUS

NASDAQ:VVUS

VIVUS, Inc. engages in the development and commercialization of novel therapeutic products. The firm's products are indicated for the treatment of obese and overweight patients, exocrine pancreatic insufficiency, and erectile dysfunction. Its products include PANCREAZE, Qsymia, and STENDRA/SPEDRA. The company was founded by Virgil A. Place in April 16, 1991 and is headquartered in Campbell, CA.

XTL Biopharmaceuticals

NASDAQ:XTLB

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial